Loading clinical trials...
Loading clinical trials...
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease to Assess the Efficacy in Reducing Urinary Protein and Maintaining Podocyte Density and Function
Conditions
Interventions
Bremelanotide
RAAS inhibition therapy
Locations
9
United States
California Institute of Renal Research
Chula Vista, California, United States
California Institute of Renal Research DBA - Balboa Research
La Mesa, California, United States
Georgia Nephrology, LLC DBA -GA Nephrology Research Institute
Decatur, Georgia, United States
Georgia Nephrology, LLC [DBA] GA Nephrology Research Institute
Lawrenceville, Georgia, United States
Brookview Hills Research Associates, LLC
Winston-Salem, North Carolina, United States
Northeast Research Center, LLC
Bethlehem, Pennsylvania, United States
Start Date
December 26, 2022
Primary Completion Date
April 26, 2024
Completion Date
April 26, 2024
Last Updated
October 17, 2024
NCT07547098
NCT04939935
NCT06278207
NCT07493642
NCT07241390
NCT04634916
Lead Sponsor
Palatin Technologies, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions